Summary of histopathologic analysis of leukemic infiltration in brain
| Treatment . | CNS symptoms . | Death . | Striatum . | Thalamus . | Brainstem/pons . | Cerebellum . |
|---|---|---|---|---|---|---|
| None* | No | Killed | 0 | 0 | 0 | 0 |
| None* | No | Radiation | 0 | 0 | 0 | 0 |
| None | No | Leukemia | 0 | 0 | 0 | 0 |
| Dasatinib | No | Leukemia | 1 | 1 | 1 | 2 |
| Dasatinib | No | Leukemia | 1 | 1 | 1 | 1 |
| Dasatinib | Yes | Leukemia | 3 | 2 | 4 | 2 |
| Dasatinib + plerixafor | Yes | Killed because of neurosymptoms | 2 | 2 | 2 | 4 |
| Dasatinib + plerixafor | Yes | Killed because of neurosymptoms | 1 | 3 | 4 | 1 |
| Dasatinib + plerixafor | Yes | Killed because of neurosymptoms | 3 | 3 | 4 | 4 |
| Treatment . | CNS symptoms . | Death . | Striatum . | Thalamus . | Brainstem/pons . | Cerebellum . |
|---|---|---|---|---|---|---|
| None* | No | Killed | 0 | 0 | 0 | 0 |
| None* | No | Radiation | 0 | 0 | 0 | 0 |
| None | No | Leukemia | 0 | 0 | 0 | 0 |
| Dasatinib | No | Leukemia | 1 | 1 | 1 | 2 |
| Dasatinib | No | Leukemia | 1 | 1 | 1 | 1 |
| Dasatinib | Yes | Leukemia | 3 | 2 | 4 | 2 |
| Dasatinib + plerixafor | Yes | Killed because of neurosymptoms | 2 | 2 | 2 | 4 |
| Dasatinib + plerixafor | Yes | Killed because of neurosymptoms | 1 | 3 | 4 | 1 |
| Dasatinib + plerixafor | Yes | Killed because of neurosymptoms | 3 | 3 | 4 | 4 |
The presence of GFP-positive infiltrates in various brain structures, as established by anti-GFP immunohistochemistry with a semiquantitative scheme of assessment: 1 indicates perivascular leukemic infiltrates; 2, nodular infiltrates < 0.5 mm; 3, nodular infiltrates 0.5-1 mm; and 4, nodular infiltrates > 1 mm. The presence of CNS symptoms was most closely associated with involvement of the brainstem and pons by nodular leukemic infiltrates, although the number of animals undergoing necropsy examination was too small to establish a statistically significant association between treatment and specific pathologic findings.
Nonleukemic mice that were killed to use as controls.